Convallatoxin is a glycoside extracted from Convallaria majalis. Convallatoxin is also isolated from the trunk bark of Antiaris toxicaria. It is a cardenolide glycoside that consists of strophanthidin having a 6-deoxy-α-L-mannopyranosyl (L-rhamnosyl) group attached at position 3. Convallatoxin is widely used as a cardiac glycoside in acute and chronic congestive heart-failure and paroxysmal tachycardia, with many effects and underlying protective mechanisms on inflammation and cellular proliferation. It can inhibit the Na+,K+-ATPase in congestive heart failure or arrythmias. Convallatoxin has been shown to be a dual inducer of autophagy and apoptosis, it inhibits angiogenesis in vitro and in vivo. Convallatoxin, exhibits antiproliferative properties against a number of cancer types. Convallatoxin presents antiproliferative effects against colorectal cancer cells in culture and that the resulting cell death is independent of the p53 tumor suppressor. Thus convallatoxin may be useful in the treatment of cancers that harbor inactivating mutations in the p53 signaling pathway.